Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2

SUPPLEMENTARY MATERIALS AND METHODS
Chemicals
Celecoxib (4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, 200 mM stock solution; Chemos GmbH, Regenstauf, Germany); imatinib (IUPAC name: 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl] benzamide; 50 mM stock solution), LKT Laboratories Inc., St. Paul, MN, USA; metformin (1,1-dimethylbiguanide hydrochloride, 200 mM stock solution; Selleckchem GmbH, Munich, Germany); rofecoxib (3-(4-methylsulfonylphenyl)-4-phenyl-2H-furan-5-one, 50 mM stock solution; MSD Inc., Milan, Italy); MG132 (Z-Leu-Leu-Leu, 50 mM stock solution), BIO (10 mM stock solution), STO-609 (10 mg/ mL stock solution), all purchased from Sigma-Aldrich Inc., Milan, Italy; these compounds, with the exception of metformin (reconstituted in milliQ water), were dissolved in 100% dimethyl sulfoxide (DMSO) and stored at +4 or -20 °C, according to manufacturers' specifications. Working concentrations of these compounds were freshly prepared for each experiment by diluting DMSO to 0.1% in milliQ (MilliPore) water.
Antibodies
The following primary antibodies were used: anti b-actin (clone AC-15 Sigma-Aldrich Inc., Milan, Italy); anti-COX1 (clone H-62, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA); anti-COX2 (clone C-20, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA); antic-Myc (clone 9E10, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA); anti-b-catenin (clone 14, BD Bioscience, Milan, Italy); anti-active b-catenin (nonphospho ser33/37/thr41, Cell Signaling Technology Inc., Danvers, MA, USA); anti-phospho-AMPKa (thr172 clone 40H9) and AMPK-a (Cell Signaling Technology Inc., Danvers, MA, USA); anti-phospho-GSK-3b (ser9) (abcam Plc., Cambridge, UK) and anti-GSK-3b (Cell Signaling Technology Inc., Danvers, MA, USA); antiphospho-Akt (thr308) (abcam Plc., Cambridge, UK); anti-phospho-Akt (ser473-D9E) and anti-pan-Akt (Cell Signaling Technology Inc., Danvers, MA, USA); anti-phospho-mTOR (Ser2448), anti-phospho-mTOR (ser2481) and anti-pan-mTOR (clone 7C10) (Cell Signaling Technology Inc., Danvers, MA, USA); antiphospho-p70 S6 Kinase (thr389) and anti-p70 S6 Kinase (Cell Signaling Technology Inc., Danvers, MA, USA); anti-phospho-4E-BP1 (thr37/46) and anti-4E-BP1 (Cell Signaling Technology Inc., Danvers, MA, USA).
RT-PCR
After an initial denaturation step at 95°C (10 min), each primer set was used (through 40 cycles of amplification) as follows: human CTNNB1, 5'-ACCAGCGCCGTACGTCCAT-3' forward and 3'-GC TAGGATGTGAAGGGCTCCG-5' reverse (104-bp amplicon), 60°C annealing temperature; human c-myc, 5'-CAAAGACAGCGGCAGCCC-3' forward and 3'-GCG AGGCGCAGGACTTG-5' reverse (164-bp amplicon), 64.4°C annealing temperature; human p16
INK4a
, 5'-CAACCTGGGGCGACTTCAG-3' forward and 3'-GA CCAGCCAGCCCCTCC-5' reverse (201-bp amplicon); 61.7°C annealing temperature.
GAPD was assessed using the 5'-CAA GGTCATCCATGACAACTTTG-3' forward and the 3'-GGGCAATCCACAGTCTTCTG-5' reverse primer (90-bp amplicon), 60°C annealing temperature.
Lentivirus packaging and infections
Lentiviral supernatants were prepared, according to manufacturer's instructions (GE-Dharmacon, UK), using HEK-293T cell lines for virus packaging. Cells were transfected with a mix (4:3:1) of pGIPZ, psPAX2 (carrying the HIV-derived gag/pol, rev and tat sequences) and pMD2.G plasmids (coding for the env protein of the Vesicular Stomatitis Virus G, required for virion pseudotyping) using the METAFECTENE ® PRO reagent (Biontex Laboratories GmbH, Germany). Lentiviral particles were concentrated after two steps of centrifugation (1500 g, 4°C) in a solution containing polyethylene glycol (PEG MW 8000, Sigma Aldrich Inc., Milan, Italy) and then re-suspended in PBS (1/50 of the initial volume).
Titration was performed on HeLa cells infected with serial dilutions (1:5) of the viral suspension. Infection efficiency was calculated by assessing, through flow cytometry, percentages of cells expressing the tGFP reporter gene contained in the pGIPZ plasmid.
Infections were carried out by spinoculation procedure. Briefly, 1x10 6 cells/mL, plated in 6-well plates, were exposed to viruses at a concentration of 10 multiplicity of infection (MOI) in presence of 8 µg/mL of Polybrene ® (Sigma Aldrich Inc., Milan, Italy). Incubation with viruses was allowed upon centrifugation for 45 min at 1,260 rpm; next, cells were incubated for 5 hours at 37°C before being switched to regular medium. Immunoblots were performed by using primary antibodies specific for: β-catenin (β-cat); p70S6 kinase (p70S6K) or its active form, phosphorylated on thr-389 (p-p70S6K); GSK3β or its inactive form phosphorylated on ser-9 (p-GSK-3b); Akt or its active forms phosphorylated either on ser-473 (p-Akt ser473) or thr-308 (p-Akt thr308). Optical densities of β-catenin immuno-reactive bands were normalised by the intensity of b-actin in order to calculate treatment-to-control (OSU-03012/CTRL) ratios. Controls were obtained by treating cells with 0.1 % DMSO. Optical densities of total p70S6K, GSK3β and Akt were assessed and used to calculate ratios to their phosphorylated counterparts. All values are displayed underneath.
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